Were Jack R. Lazar’s Astera Labs (ALAB) share sales pre-planned?

Yes. A footnote states the sales occurred automatically under a Rule 10b5-1 trading plan adopted on December 2, 2025. Such plans pre-schedule trades, meaning the timing of these sales was determined in advance rather than based on contemporaneous market or company developments.

Astera Labs (ALAB) director sells 10,000 shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Astera Labs director Jack R. Lazar reported net share sales and an equity grant. On June 4, 2026 he sold 10,000 shares of Common Stock in open-market transactions under a Rule 10b5-1 trading plan at prices between $339.5600 and $362.8405 per share, and now directly holds 85,688 shares. He also received a grant of 837 restricted stock units that vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to continued service.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($3,551,679)

Net Sell 19 txns

Insider LAZAR JACK R

Role null

Sold 10,000 shs ($3.55M)

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	837	$0.00	--
Sale	Common Stock	879	$362.8405	$319K
Sale	Common Stock	854	$361.1061	$308K
Sale	Common Stock	1,116	$360.0879	$402K
Sale	Common Stock	877	$359.3267	$315K
Sale	Common Stock	883	$358.136	$316K
Sale	Common Stock	566	$356.9442	$202K
Sale	Common Stock	946	$355.1273	$336K
Sale	Common Stock	373	$354.3839	$132K
Sale	Common Stock	1,101	$352.9665	$389K
Sale	Common Stock	318	$351.7187	$112K
Sale	Common Stock	17	$351.13	$6K
Sale	Common Stock	423	$349.9557	$148K
Sale	Common Stock	193	$347.8389	$67K
Sale	Common Stock	238	$346.2717	$82K
Sale	Common Stock	246	$345.2366	$85K
Sale	Common Stock	243	$344.0294	$84K
Sale	Common Stock	527	$342.5453	$181K
Sale	Common Stock	200	$339.56	$68K

Holdings After Transaction: Common Stock — 85,688 shares (Direct, null)

Footnotes (1)

These shares represent an award of restricted stock units ("RSUs") granted on June 4, 2026 (the "Grant Date") under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award vests in full upon the earlier of (i) the first anniversary of the Grant Date or (ii) the date of the next annual stockholder meeting of the Company following the Grant Date, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Includes deferred stock units and dividend equivalent units. The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $362.5300 to $363.4350, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $360.8100 to $361.6600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $359.7450 to $360.6600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $358.8000 to $359.6400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $357.8650 to $358.6000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $356.6600 to $357.5750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $354.6200 to $355.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $354.0600 to $354.5500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $352.5400 to $353.5200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $351.5250 to $352.4850, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $349.1050 to $350.0100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $347.7700 to $347.8600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $346.2700 to $346.6650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $344.6650 to $345.6250, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $343.9250 to $344.6200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $342.5200 to $343.4600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 10,000 shares Sale price range: $339.5600–$362.8405 per share RSUs granted: 837 units +3 more

6 metrics

Shares sold 10,000 shares Open-market sales on June 4, 2026

Sale price range $339.5600–$362.8405 per share Common Stock open-market transactions

RSUs granted 837 units Restricted stock unit award on June 4, 2026

Shares owned after 85,688 shares Direct ownership following reported transactions

Net share change direction net-sell of 10,000 shares Transaction summary for this Form 4

Number of sale transactions 18 transactions Separate open-market sale entries on June 4, 2026

Key Terms

restricted stock units ("RSUs"), Astera Labs, Inc. 2024 Stock Option and Incentive Plan, Rule 10b5-1 trading plan, deferred stock units, +1 more

5 terms

restricted stock units ("RSUs") financial

"These shares represent an award of restricted stock units ("RSUs") granted on June 4, 2026"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Astera Labs, Inc. 2024 Stock Option and Incentive Plan financial

"granted on June 4, 2026 under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan"

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

deferred stock units financial

"Includes deferred stock units and dividend equivalent units."

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

dividend equivalent units financial

"Includes deferred stock units and dividend equivalent units."

Dividend equivalent units are bookkeeping credits that mirror cash dividends paid on actual shares, granted to holders of stock-based awards such as restricted stock units or deferred compensation. They matter to investors because they increase a company’s reported employee compensation cost and can lead to issuance of more shares or cash payouts over time, similar to extra pay linked to ownership that affects shareholder dilution and corporate cash flow.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/08/2026 - 08:26 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAZAR JACK R

(Last)

(First)

(Middle)

C/O ASTERA LABS, INC.

2345 NORTH FIRST STREET

(Street)

SAN JOSE

CALIFORNIA

95131

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Astera Labs, Inc. [ ALAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/04/2026		A		837⁽¹⁾	A	$0	85,688⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		879	D	$362.8405⁽⁴⁾	84,809⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		854	D	$361.1061⁽⁵⁾	83,955⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		1,116	D	$360.0879⁽⁶⁾	82,839⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		877	D	$359.3267⁽⁷⁾	81,962⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		883	D	$358.136⁽⁸⁾	81,079⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		566	D	$356.9442⁽⁹⁾	80,513⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		946	D	$355.1273⁽¹⁰⁾	79,567⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		373	D	$354.3839⁽¹¹⁾	79,194⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		1,101	D	$352.9665⁽¹²⁾	78,093⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		318	D	$351.7187⁽¹³⁾	77,775⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		17	D	$351.13	77,758⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		423	D	$349.9557⁽¹⁴⁾	77,335⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		193	D	$347.8389⁽¹⁵⁾	77,142⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		238	D	$346.2717⁽¹⁶⁾	76,904⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		246	D	$345.2366⁽¹⁷⁾	76,658⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		243	D	$344.0294⁽¹⁸⁾	76,415⁽²⁾	D
Common Stock	06/04/2026		S⁽³⁾		527	D	$342.5453⁽¹⁹⁾	75,888	D
Common Stock	06/04/2026		S⁽³⁾		200	D	$339.56⁽¹⁹⁾	75,688	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares represent an award of restricted stock units ("RSUs") granted on June 4, 2026 (the "Grant Date") under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award vests in full upon the earlier of (i) the first anniversary of the Grant Date or (ii) the date of the next annual stockholder meeting of the Company following the Grant Date, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

2. Includes deferred stock units and dividend equivalent units.

3. The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2025.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $362.5300 to $363.4350, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $360.8100 to $361.6600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $359.7450 to $360.6600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $358.8000 to $359.6400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $357.8650 to $358.6000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $356.6600 to $357.5750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $354.6200 to $355.5800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

11. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $354.0600 to $354.5500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

12. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $352.5400 to $353.5200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

13. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $351.5250 to $352.4850, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

14. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $349.1050 to $350.0100, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

15. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $347.7700 to $347.8600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

16. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $346.2700 to $346.6650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

17. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $344.6650 to $345.6250, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

18. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $343.9250 to $344.6200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

19. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $342.5200 to $343.4600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Philip Mazzara, Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Astera Labs (ALAB) director Jack R. Lazar report in this Form 4?

Jack R. Lazar reported selling 10,000 shares of Astera Labs Common Stock and receiving 837 restricted stock units. After these transactions, he directly owns 85,688 shares, reflecting both open-market sales and a new equity grant tied to continued board service.

How many Astera Labs (ALAB) shares did Jack R. Lazar sell and at what prices?

He sold 10,000 shares of Astera Labs Common Stock in multiple open-market trades. Reported transaction prices ranged from $339.5600 to $362.8405 per share, with several entries showing specific weighted average prices for different sale blocks executed on June 4, 2026.

What equity award did Jack R. Lazar receive from Astera Labs (ALAB)?

He received an award of 837 restricted stock units under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Each RSU represents a right to one share of Common Stock, vesting in full on the earlier of the first anniversary of the June 4, 2026 grant or the next annual meeting.

When do Jack R. Lazar’s new Astera Labs (ALAB) RSUs vest?

The 837 RSUs vest in full on the earlier of the first anniversary of the June 4, 2026 grant date or the next annual stockholder meeting. Vesting is conditioned on his continuous service relationship with Astera Labs through the applicable vesting date specified in the award terms.

How many Astera Labs (ALAB) shares does Jack R. Lazar own after these transactions?

Following the reported June 4, 2026 transactions, Jack R. Lazar directly owns 85,688 shares of Astera Labs Common Stock. This figure reflects both the 10,000 shares sold in open-market transactions and the 837-share restricted stock unit award credited to his holdings in the filing.